Spravato (Esketamine HCl) Patent Expiration, LOE Window & CMS Spending

Spravato (Esketamine HCl) by Johnson & Johnson: FDA Orange Book LOE 2040-02-18, 0 AB generics, $299.2M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN211243 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-02-18
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$299.2M
2024 Medicare Part D Spend$128.1M
2024 Medicaid Spend$171.1M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 22.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.